Prediction of future insulin-deficiency in glutamic acid decarboxylase autoantibody enzyme-linked immunosorbent assay-positive patients with slowly-progressive type 1 diabetes.

Glutamic acid decarboxylase Prediction Slowly-progressive type 1 diabetes

Journal

Journal of diabetes investigation
ISSN: 2040-1124
Titre abrégé: J Diabetes Investig
Pays: Japan
ID NLM: 101520702

Informations de publication

Date de publication:
07 Mar 2024
Historique:
revised: 18 02 2024
received: 24 09 2023
accepted: 22 02 2024
medline: 7 3 2024
pubmed: 7 3 2024
entrez: 7 3 2024
Statut: aheadofprint

Résumé

This study aimed to identify risk factors that contribute to the progression of slowly-progressive type 1 diabetes by evaluating the positive predictive value (PPV) of factors associated with the progression to an insulin-dependent state. We selected 60 slowly-progressive type 1 diabetes patients who tested positive for glutamic acid decarboxylase autoantibodies (GADA) at diagnosis from the Japanese Type 1 Diabetes Database Study. GADA levels in these patients were concurrently measured using both radioimmunoassay (RIA) and enzyme-linked immunosorbent assay (ELISA) techniques. Compared with the non-progressor group (fasting C-peptide [F-CPR] levels maintained ≥0.6 ng/mL), the progressor group showed a younger age at diagnosis, lower body mass index (BMI), lower F-CPR levels and a higher prevalence of insulinoma-associated antigen-2 autoantibodies (IA-2A). The PPV of RIA-GADA increased from 56.3 to 70.0% in the high titer group (≥10 U/mL), and further increased to 76.9, 84.2, 81.0 and 75.0% when combined with specific thresholds for age at diagnosis <47 years, BMI <22.6 kg/m Our findings show that, unlike RIA-GADA, ELISA-GADA shows no association between GADA titers and the risk of progression to an insulin-dependent state. The PPV improves when age at diagnosis, BMI and F-CPR levels are considered in combination.

Identifiants

pubmed: 38451108
doi: 10.1111/jdi.14178
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : The National Center for Global Health and Medicine
ID : 19A1008

Informations de copyright

© 2024 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd.

Références

Kawasaki E, Matsuura N, Eguchi K. Type 1 diabetes in Japan. Diabetologia 2006; 49: 828-836.
Buzzetti R, Maddaloni E, Gaglia J, et al. Adult-onset autoimmune diabetes. Nat Rev Dis Primers 2022; 8: 63.
Kawasaki E, Shimada A, Imagawa A, et al. Bivalent GAD autoantibody ELISA improves clinical utility and risk prediction for adult autoimmune diabetes. J Diabetes Investig 2023; 14: 570-581.
Kasuga A, Maruyama T, Nakamoto S, et al. High-titer autoantibodies against glutamic acid decarboxylase plus autoantibodies against insulin and IA-2 predicts insulin requirement in adult diabetic patients. J Autoimmun 1999; 12: 131-135.
Kawasaki E, Nakamura K, Kuriya G, et al. Autoantibodies to insulin, insulinoma-associated antigen-2, and zinc transporter 8 improve the prediction of early insulin requirement in adult-onset autoimmune diabetes. J Clin Endocrinol Metab 2010; 95: 707-713.
Chujo D, Imagawa A, Yasuda K, et al. Japanese type 1 diabetes database study (TIDE-J): Rationale and study design. Diabetol Int 2021; 13: 288-294.
Tanaka S, Ohmori M, Awata T, et al. Diagnostic criteria for slowly progressive insulin-dependent (type 1) diabetes mellitus (SPIDDM) (2012): Report by the Committee on Slowly Progressive Insulin-Dependent (Type 1) Diabetes Mellitus of the Japan Diabetes Society. Diabetol Int 2015; 6: 1-7.
Kawasaki E, Shimada A, Imagawa A, et al. Comparing the clinical significance and antigen specificity of insulinoma-associated antigen-2 autoantibodies between radioimmunoassay and enzyme-linked immunosorbent assay in Japanese patients with type 1 diabetes. J Diabetes Investig 2023; 14: 58-66.
Zhou Z, Xiang Y, Ji L, et al. Frequency, immunogenetics, and clinical characteristics of latent autoimmune diabetes in China (LADA China study): A nationwide, multicenter, clinic-based cross-sectional study. Diabetes 2013; 62: 543-550.
Kawasaki E. Anti-islet autoantibodies in type 1 diabetes. Int J Mol Sci 2023; 24: 10012.
Bingley PJ, Bonifacio E, Mueller PW. Diabetes antibody standardization program: First assay proficiency evaluation. Diabetes 2003; 52: 1128-1136.
Kawasaki E, Okada A, Uchida A, et al. Discrepancy of glutamic acid decarboxylase 65 autoantibody results between RSR radioimmunoassay and enzyme-linked immunosorbent assay in patients with type 1 diabetes is related to autoantibody affinity. J Diabetes Investig 2019; 10: 990-996.
Miao D, Guyer KM, Dong F, et al. GAD65 autoantibodies detected by electrochemiluminescence assay identify high risk for type 1 diabetes. Diabetes 2013; 62: 4174-4178.
Lampasona V, Pittman DL, Williams AJ, et al. Islet Autoantibody Standardization Program 2018 workshop: Interlaboratory comparison of glutamic acid decarboxylase autoantibody assay performance. Clin Chem 2019; 65: 1141-1152.
Mayr A, Schlosser M, Grober N, et al. GAD autoantibody affinity and epitope specificity identify distinct immunization profiles in children at risk for type 1 diabetes. Diabetes 2007; 56: 1527-1533.
Krause S, Landherr U, Agardh CD, et al. GAD autoantibody affinity in adult patients with latent autoimmune diabetes, the study participants of a GAD65 vaccination trial. Diabetes Care 2014; 37: 1675-1680.
Bottazzo GF, Bosi E, Cull CA, et al. IA-2 antibody prevalence and risk assessment of early insulin requirement in subjects presenting with type 2 diabetes (UKPDS 71). Diabetologia 2005; 48: 703-708.
Gu Y, Jia X, Vartak T, et al. Improving clinical utility of GAD65 autoantibodies by electrochemiluminescence assay and clinical phenotype when identifying autoimmune adult-onset diabetes. Diabetologia 2021; 64: 2052-2060.

Auteurs

Eiji Kawasaki (E)

Diabetes Center, Shin-Koga Hospital, Kurume, Japan.

Takuya Awata (T)

Pancreatic Islet Cell Transplantation Center, National Center for Global Health and Medicine, Tokyo, Japan.

Hiroshi Ikegami (H)

Department of Endocrinology, Metabolism and Diabetes, Kindai University Faculty of Medicine, Osaka, Japan.

Akihisa Imagawa (A)

Department of Internal Medicine (I), Osaka Medical and Pharmaceutical University, Takatsuki, Japan.

Yoichi Oikawa (Y)

Department of Endocrinology and Diabetes, School of Medicine, Saitama Medical University, Iruma, Japan.

Haruhiko Osawa (H)

Department of Diabetes and Molecular Genetics, Ehime University Graduate School of Medicine, Toon, Japan.

Takeshi Katsuki (T)

Department of Diabetes and Endocrinology, Tokyo Saiseikai Central Hospital, Tokyo, Japan.

Norio Kanatsuna (N)

Department of Internal Medicine (I), Osaka Medical and Pharmaceutical University, Takatsuki, Japan.

Ryoichi Kawamura (R)

Department of Diabetes and Molecular Genetics, Ehime University Graduate School of Medicine, Toon, Japan.

Junji Kozawa (J)

Department of Metabolic Medicine, Graduate School of Medicine, Osaka University, Suita, Japan.

Noriko Kodani (N)

Department of Diabetes, Endocrinology, and Metabolism, Center Hospital of the National Center for Global Health and Medicine, Tokyo, Japan.

Tetsuro Kobayashi (T)

Okinaka Memorial Institute for Medical Research, Tokyo, Japan.

Akira Shimada (A)

Department of Endocrinology and Diabetes, School of Medicine, Saitama Medical University, Iruma, Japan.

Masayuki Shimoda (M)

Pancreatic Islet Cell Transplantation Center, National Center for Global Health and Medicine, Tokyo, Japan.

Kazuma Takahashi (K)

Iwate Prefectural University, Takizawa, Japan.

Daisuke Chujo (D)

Center for Clinical Research, Toyama University Hospital, Toyama, Japan.

Tetsuro Tsujimoto (T)

Department of Diabetes and Endocrinology, Toranomon Hospital Kajigaya, Kawasaki, Japan.

Kyoichiro Tsuchiya (K)

Department of Diabetes and Endocrinology, University of Yamanashi Hospital, Yamanashi, Japan.

Aiko Terakawa (A)

Department of Diabetes, Endocrinology, and Metabolism, Center Hospital of the National Center for Global Health and Medicine, Tokyo, Japan.

Jungo Terasaki (J)

Department of Internal Medicine (I), Osaka Medical and Pharmaceutical University, Takatsuki, Japan.

Kan Nagasawa (K)

Division of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine, Iwate Medical University, Yahaba, Japan.

Shinsuke Noso (S)

Department of Endocrinology, Metabolism and Diabetes, Kindai University Faculty of Medicine, Osaka, Japan.

Tomoyasu Fukui (T)

Division of Diabetes and Endocrinology, Showa University School of Medicine, Tokyo, Japan.

Ichiro Horie (I)

Department of Endocrinology and Metabolism, Nagasaki University Hospital, Nagasaki, Japan.

Kazuki Yasuda (K)

Department of Diabetes, Endocrinology, and Metabolism, Kyorin University, Mitaka, Japan.

Hisafumi Yasuda (H)

Division of Health Sciences, Department of Public Health, Kobe University Graduate School of Health Sciences, Kobe, Japan.

Hidekatsu Yanai (H)

Department of Endocrinology and Metabolism, Kohnodai Hospital, National Center for Global Health and Medicine, Ichikawa, Japan.

Toshiaki Hanafusa (T)

Sakai City Medical Center, Sakai, Japan.

Hiroshi Kajio (H)

Department of Diabetes, Endocrinology, and Metabolism, Center Hospital of the National Center for Global Health and Medicine, Tokyo, Japan.

Classifications MeSH